TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8002646

Group type: EXPERIMENTAL
Intervention: Nicotinamide and tetracycline (500 mg nicotinamide three times daily, 500 mg tetracycline four times daily)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Prednisone therapy
Number of subjects: 20
Study: 2562200

Group type: EXPERIMENTAL
Intervention: TAS (Y set with two short branches filled with electrolytic chloroxidizer solution)
Number of subjects: 60

Group type: COMPARATOR
Intervention: TCS (traditional Y set)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: TAS
Number of subjects: 60

Group type: COMPARATOR
Intervention: TCS
Number of subjects: 60
Study: 31974091

Group type: EXPERIMENTAL
Intervention: Dual-ring circular plastic wound protector with circular polyethylene drape
Number of subjects: 458

Group type: COMPARATOR
Intervention: Conventional surgical dressing gauze
Number of subjects: 458
Study: 31138170

Group type: EXPERIMENTAL
Intervention: Minoxidil
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 29233169

Group type: COMPARATOR
Intervention: SIGMA mHealth intervention (gamified mobile application based on CBT principles) for 2 months with a 3-month follow-up.
Number of subjects: 0
Study: 25339155

Group type: EXPERIMENTAL
Intervention: Fibrin glue with a low concentration of thrombin (ARTISS, Baxter) applied under the abdominal flap
Number of subjects: 30

Group type: COMPARATOR
Intervention: Traditional surgery
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fibrin glue with a low concentration of thrombin (ARTISS, Baxter)
Number of subjects: 30
Study: 24384675

Group type: EXPERIMENTAL
Intervention: One-contact referral to locally organized physical activities
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: One-contact provision of a walking program
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: 10-week multiple-contact physical activity coaching based on the Self-Determination Theory
Number of subjects: 442

Group type: COMPARATOR
Intervention: All programs
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 442
Study: 21969261

Group type: EXPERIMENTAL
Intervention: GCQ supplement (1200 mg glucosamine hydrochloride, 60 mg chondroitin sulfate, and 45 mg quercetin glycosides per day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: GCQ supplement
Number of subjects: 40
Study: 19351807

Group type: EXPERIMENTAL
Intervention: Exercise training (5 days/week, 60 min/day, 75% Vo(2 max)) combined with eucaloric diet (EX)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Exercise training (5 days/week, 60 min/day, 75% Vo(2 max)) combined with hypocaloric diet (EX-HYPO)
Number of subjects: 19
Study: 17207153

Group type: EXPERIMENTAL
Intervention: Safer sex practices
Number of subjects: 2595

Group type: EXPERIMENTAL
Intervention: Modification of feeding behaviour due to HIV concerns
Number of subjects: 2595

Group type: EXPERIMENTAL
Intervention: Concern about own HIV status
Number of subjects: 2595

Group type: EXPERIMENTAL
Intervention: Abstinence to prevent HIV
Number of subjects: 2595

Group type: EXPERIMENTAL
Intervention: No new HIV infections among abstaining single mothers
Number of subjects: 2595
Study: 15241585

Group type: EXPERIMENTAL
Intervention: Creatinine clearance (CrCl) < 65 ml/min
Number of subjects: 186

Group type: COMPARATOR
Intervention: Creatinine clearance (CrCl) >= 65 ml/min
Number of subjects: 186
Study: 12452237

Group type: EXPERIMENTAL
Intervention: Lidocaine 1.5 mg x kg(‐1) and succinylcholine 1.5 mg x kg(‐1) (Group LS)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Normal saline and succinylcholine 1.5 mg x kg(‐1) (Group PS)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Normal saline and rocuronium 0.6 mg x kg(‐1) (Group PR)
Number of subjects: 135
Study: 10352377

Group type: EXPERIMENTAL
Intervention: Mahonia aquifolium ointment
Number of subjects: 49

Group type: COMPARATOR
Intervention: Dithranol
Number of subjects: 49
Study: 8520743

Group type: COMPARATOR
Intervention: Antacids (30 mL every 4 h)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Sucralfate (1 g every 4 h)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Intragastric acidity
Number of subjects: 141
Study: 1770194

Group type: EXPERIMENTAL
Intervention: 1200-kcal/day diet
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 33% calorie-restricted diet (1600-1800 kcal/day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Prophylactic insulin
Number of subjects: 12

Group type: COMPARATOR
Intervention: 2400-kcal/day diet
Number of subjects: 12
Study: 7060036

Group type: EXPERIMENTAL
Intervention: iv melphalan (16 mg/m2 every 2 weeks for four doses, followed by a single dose every 4 weeks)
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: iv melphalan (50% dose reduction)
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: oral melphalan (0.15 mg/kg/day for 7 days, followed by 0.05 mg/kg/day after recovery from the wbc count nadir)
Number of subjects: 295
Study: 31012740

Group type: EXPERIMENTAL
Intervention: Tactile based technology (e.g., Braille books, Braille slate and stylus)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Visual based technology (e.g., video magnifiers)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Walking canes
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Audible balls
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Screen readers
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Math and science learning devices
Number of subjects: 250
Study: 30653355

Group type: EXPERIMENTAL
Intervention: Board games training group
Number of subjects: 27

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 27
Study: 29166732

Group type: EXPERIMENTAL
Intervention: PEG‐rhG‐CSF
Number of subjects: 410
Study: 25820754

Group type: EXPERIMENTAL
Intervention: Pegfilgrastim 60 µg/kg/cycle
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Pegfilgrastim 100 µg/kg/cycle
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Pegfilgrastim 120 µg/kg/cycle
Number of subjects: 171

Group type: COMPARATOR
Intervention: Filgrastim 5 µg/kg/day
Number of subjects: 171
Study: 23448344

Group type: EXPERIMENTAL
Intervention: Prasugrel reloading (20 mg)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Clopidogrel reloading (300 mg)
Number of subjects: 76
Study: 20509027

Group type: EXPERIMENTAL
Intervention: High-dose pegylated interferon α‐2b (peginterferon α‐2b) 6 μg/(kg week) subcutaneously for 8 weeks (induction) then 3 μg/(kg week) for 4 weeks (maintenance)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: High-dose pegylated interferon α‐2b (peginterferon α‐2b)
Number of subjects: 32
Study: 20108776

Group type: EXPERIMENTAL
Intervention: Kurarinol (600 mg glucose injection IV once a day for 1 month, followed by Kurarinol capsule orally three times a day for 2 months)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Silybin Meglumine Tablets (used in control group, same method and dosage as treatment group)
Number of subjects: 74
Study: 17161432

Group type: EXPERIMENTAL
Intervention: Human Patient Simulator (HPS) in the shock skills station
Number of subjects: 44

Group type: COMPARATOR
Intervention: Traditional teaching method (Control group)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Human Patient Simulator (HPS)
Number of subjects: 44
Study: 15197149

Group type: EXPERIMENTAL
Intervention: Current NSAID use
Number of subjects: 4975

Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 4975

Group type: COMPARATOR
Intervention: Aspirin and concurrent NSAIDs use
Number of subjects: 4975

Group type: COMPARATOR
Intervention: Ibuprofen and aspirin taken concomitantly
Number of subjects: 4975
Study: 11496599

Group type: EXPERIMENTAL
Intervention: Flocath (Ruschcare)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Lofric (Astratech)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Easycath (Coloplast)
Number of subjects: 27
Study: 9593111

Group type: EXPERIMENTAL
Intervention: APO‐A1 major locus
Number of subjects: 970

Group type: EXPERIMENTAL
Intervention: APO‐A1 effect on HDL2‐C
Number of subjects: 970
Study: 7530738

Group type: EXPERIMENTAL
Intervention: T3Ag
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Removal of CD8+ T cells from peripheral blood mononuclear cells
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: T3Ag stimulation
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: T3Ag-stimulated anti-C100-3 antibody production
Number of subjects: 32
Study: 3379229

Group type: EXPERIMENTAL
Intervention: Sulfited lettuce
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Dried apricots
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: White grape juice
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Dehydrated potatoes (mashed potatoes)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Mushrooms
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Sulfited shrimp
Number of subjects: 8
Study: 29584462

Group type: EXPERIMENTAL
Intervention: Caffeinated gum (200 mg caffeine)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (0 mg caffeine)
Number of subjects: 10
Study: 28734830

Group type: EXPERIMENTAL
Intervention: Active choice email plus $100 incentive
Number of subjects: 2245

Group type: EXPERIMENTAL
Intervention: Active choice email
Number of subjects: 2245

Group type: COMPARATOR
Intervention: Control email with phone number for scheduling
Number of subjects: 2245
Study: 26169181

Group type: EXPERIMENTAL
Intervention: Mirabegron 50mg/day for 6 weeks
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Solifenacin 10mg/day for 6 weeks
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Combination of mirabegron 50mg/day and solifenacin 10mg/day for 6 weeks
Number of subjects: 239

Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 239
Study: 24212838

Group type: EXPERIMENTAL
Intervention: travoprost/timolol
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: latanoprost/timolol
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: bimatoprost/timolol
Number of subjects: 33
Study: 20934856

Group type: EXPERIMENTAL
Intervention: Calcium-fortified cereal-legume snack (laddoo) (500 mg of calcium carbonate)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Calcium carbonate alone (500 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Non-fortified cereal-legume snack
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Calcium-fortified cereal-legume snack (laddoo)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Calcium carbonate alone
Number of subjects: 24
Study: 19828122

Group type: EXPERIMENTAL
Intervention: Cistus extract (CYSTUS052)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 17121895

Group type: EXPERIMENTAL
Intervention: Nitroglycerin patches before operation
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Nitroglycerin treatment for 3 days before chemotherapy using DCb
Number of subjects: 17

Group type: COMPARATOR
Intervention: No nitroglycerin treatment
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Nitroglycerin treatment
Number of subjects: 17
Study: 15578397

Group type: EXPERIMENTAL
Intervention: Intermittent rifampin and pyrazinamide (RZ) therapy, given twice weekly for 2 months
Number of subjects: 423
Study: 11721754

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg once daily
Number of subjects: 3510

Group type: COMPARATOR
Intervention: Omeprazole 20 mg once daily
Number of subjects: 3510
Study: 9305416

Group type: EXPERIMENTAL
Intervention: Loxiglumide (CCK-A receptor antagonist)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline placebo infusion
Number of subjects: 12
Study: 7894212

Group type: EXPERIMENTAL
Intervention: LDL apheresis (once a week for 3 years)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: LDL apheresis
Number of subjects: 32
Study: 2691129

Group type: EXPERIMENTAL
Intervention: Perindopril 4 mg once daily
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Perindopril with diuretic
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Perindopril with beta-blocker
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 165
Study: 4150435

Group type: EXPERIMENTAL
Intervention: Sulphasalazine
Number of subjects: 64

Group type: COMPARATOR
Intervention: Dummy tablets
Number of subjects: 64
Study: 30851740

Group type: EXPERIMENTAL
Intervention: PVI guided GDFT
Number of subjects: 76

Group type: COMPARATOR
Intervention: PPV guided GDFT
Number of subjects: 76
Study: 28460562

Group type: COMPARATOR
Intervention: Conventional straight-wire method (CG)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Damon technique (DT)
Number of subjects: 22
Study: 25651134

Group type: EXPERIMENTAL
Intervention: Postural insoles
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo insoles
Number of subjects: 20
Study: 23264396

Group type: EXPERIMENTAL
Intervention: Brand-name L-thyroxine (Synthroid)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Generic L-thyroxine (Sandoz)
Number of subjects: 31
Study: 21522070

Group type: EXPERIMENTAL
Intervention: Low-dose caffeine (Stay Alert™ gum, 85 mg caffeine)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo gum (no caffeine)
Number of subjects: 10
Study: 18555485

Group type: EXPERIMENTAL
Intervention: Cognitive training on two computerized visual attention training tasks (VT1 and VT2) for at least 40 hours
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Cognitive training on two computerized visual attention training tasks (VT1 and VT2)
Number of subjects: 32
Study: 16750456

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg and 40 mg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Esomeprazole (both doses)
Number of subjects: 28
Study: 15730653

Group type: EXPERIMENTAL
Intervention: Balanced salt solution for patients with middle and small burn area (Na(+) = 130 mmol/L)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Balanced salt solution for patients with large burn area
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Hypertonic saline resuscitation for patients with large burn area (Na(+) = 174 mmol/L)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 150
Study: 10930892

Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate (RBC) based triple therapy
Number of subjects: 17

Group type: COMPARATOR
Intervention: Proton pump inhibitor (PPI) based triple therapy
Number of subjects: 17
Study: 8965746

Group type: EXPERIMENTAL
Intervention: Combination of L-thyroxine and 150 micrograms iodine
Number of subjects: 49

Group type: COMPARATOR
Intervention: Mono-L-thyroxine treatment (control group B)
Number of subjects: 49
Study: 1507027

Group type: COMPARATOR
Intervention: Active control product
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Test products slightly better than the active control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Test products not quite as good as the active control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Student-t test applied to means of subject GI gingivitis scores
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transformations of subject GI mean gingivitis scores
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Difference in group means
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 90% confidence interval for 100*R
Number of subjects: 0
Study: 6338253

Group type: EXPERIMENTAL
Intervention: Cephalexin (10-day courses)
Number of subjects: 0
Study: 31440343

Group type: EXPERIMENTAL
Intervention: 1-hour session using a novel framework based on education literature, individual review of previously written feedback, and deliberate practice in writing comments.
Number of subjects: 157
Study: 27808415

Group type: EXPERIMENTAL
Intervention: Sodium oxybate (Xyrem)
Number of subjects: 45
Study: 26703371

Group type: EXPERIMENTAL
Intervention: 0.2% E6005
Number of subjects: 62

Group type: COMPARATOR
Intervention: 0.05% E6005
Number of subjects: 62

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 62
Study: 24778046

Group type: EXPERIMENTAL
Intervention: Bevacizumab (5 mg/kg for 6 weeks, starting at week 6 of gemcitabine therapy)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bevacizumab (5 mg/kg for 12 weeks, starting at week 1 of gemcitabine therapy)
Number of subjects: 30
Study: 22309617

Group type: EXPERIMENTAL
Intervention: Baby Business program (intervention group)
Number of subjects: 750

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 750
Study: 19730769

Group type: EXPERIMENTAL
Intervention: Closed suction drainage (CD)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Gravity drainage (GD)
Number of subjects: 110
Study: 17712126

Group type: EXPERIMENTAL
Intervention: After-school physical activity program (30 minutes homework/healthy snack time and 80 minutes physical activity)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study: 15580809

Group type: EXPERIMENTAL
Intervention: 200 mg EGCG
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 400 mg EGCG
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 800 mg EGCG
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 11425411

Group type: EXPERIMENTAL
Intervention: abciximab bolus and 24 h infusion
Number of subjects: 7800

Group type: EXPERIMENTAL
Intervention: abciximab bolus and 48 h infusion
Number of subjects: 7800

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 7800
Study: 9482293

Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal capsular polysaccharide vaccine
Number of subjects: 691

Group type: COMPARATOR
Intervention: Placebo (sodium chloride)
Number of subjects: 691
Study: 7990452

Group type: EXPERIMENTAL
Intervention: Geriatric service (study group)
Number of subjects: 40
Study: 2536896

Group type: EXPERIMENTAL
Intervention: Propranolol (10, 20, 40, and 80 mg every eight hours for one day)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Propranolol (oral dose)
Number of subjects: 20
Study: 30006792

Group type: EXPERIMENTAL
Intervention: TXT-PHE (interactive text conversations with Peer Health Educators, plus five‐times‐a‐day automated theory‐based messages, plus a weekly self‐monitoring text‐message assessment)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: TXT-Auto (daily automated messages and weekly self‐monitoring assessment)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: AO (weekly self‐monitoring assessment only)
Number of subjects: 286
Study: 28545364

Group type: EXPERIMENTAL
Intervention: Dynamic lighting system
Number of subjects: 89

Group type: COMPARATOR
Intervention: Conventional lighting
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Higher daily light exposure
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Lower daily light exposure
Number of subjects: 89
Study: 25921747

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone (50 mg) daily for 24 weeks
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 23381973

Group type: EXPERIMENTAL
Intervention: Ruxolitinib (10-100 mg single doses and 10 mg or 25 mg every 12 hours multiple doses)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 21799145

Group type: EXPERIMENTAL
Intervention: Dialysate flow rate of 800 ml/min
Number of subjects: 42

Group type: COMPARATOR
Intervention: Dialysate flow rate of 600 ml/min
Number of subjects: 42
Study: 19783805

Group type: EXPERIMENTAL
Intervention: Combined periodontal and triple therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Triple therapy alone
Number of subjects: 0
Study: 16426268

Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS in healthy volunteers
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 10 Hz rTMS in migraine patients
Number of subjects: 16
Study: 12931769

Group type: EXPERIMENTAL
Intervention: Preoperative oral sedation with diazepam and local anesthetic
Number of subjects: 13

Group type: COMPARATOR
Intervention: Local anesthetic only
Number of subjects: 13
Study: 10710578

Group type: EXPERIMENTAL
Intervention: Computer based clinical decision support system plus cardiovascular risk chart
Number of subjects: 614

Group type: EXPERIMENTAL
Intervention: Cardiovascular risk chart alone
Number of subjects: 614

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 614
Study: 9188928

Group type: EXPERIMENTAL
Intervention: Mizolastine 10 mg once daily
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Terfenadine 120 mg once daily
Number of subjects: 342

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 342
Study: 1416574

Group type: EXPERIMENTAL
Intervention: Single 1-gram dose of ciprofloxacin (single-dose group; n = 40)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: 1-gram dose of ciprofloxacin at admission and 24 hours later (2-dose group; n = 43)
Number of subjects: 128

Group type: COMPARATOR
Intervention: 500 mg of ciprofloxacin every 12 hours for 5 days (10-dose group; n = 35)
Number of subjects: 128
Study: 3889004

Group type: EXPERIMENTAL
Intervention: Cefoxitin (Mefoxin)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152

Group type: COMPARATOR
Intervention: None (absence of antibiotic prophylaxis)
Number of subjects: 152
Study: 30588994

Group type: EXPERIMENTAL
Intervention: Professional oral hygiene care, toothbrushing education, and fluoride varnish application once per week for 8 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fluoride varnish application once per week for 8 weeks (Control)
Number of subjects: 40
Study: 27726951

Group type: EXPERIMENTAL
Intervention: Stapled haemorrhoidopexy
Number of subjects: 777

Group type: COMPARATOR
Intervention: Traditional excisional surgery
Number of subjects: 777
Study: 23988443

Group type: EXPERIMENTAL
Intervention: 0.05% oxymetazoline (Vicks Sinex Micromist®) nasal spray, 100 μg dose
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sham 'spray' (untreated control)
Number of subjects: 21
Study: 24032184

Group type: EXPERIMENTAL
Intervention: Kuijiening plaster
Number of subjects: 60

Group type: COMPARATOR
Intervention: SASP
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combined therapy (Kuijiening plaster + SASP)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All treatments (Kuijiening plaster, SASP, combined therapy)
Number of subjects: 60
Study: 20216301

Group type: EXPERIMENTAL
Intervention: ART interruption (drug conservation)
Number of subjects: 134

Group type: COMPARATOR
Intervention: ART continuation (virological suppression)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 134